Prescribing trends of proton pump inhibitors and histamine blockers among children in the United Kingdom (1998–2019): A population‐based assessment

Abstract

AbstractPurposeTo describe the prescribing trends of proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) among children with gastroesophageal reflux in the United Kingdom between 1998 and 2019.MethodsWe conducted a population‐based retrospective cohort study using data from the Clinical Practice Research Datalink that included all children aged ≤18 years with a first ever diagnosis of gastroesophageal reflux between 1998 and 2019. Using negative binomial regression, we estimated crude and adjusted annual prescription rates per 1000 person‐years and corresponding 95% confidence intervals (CIs) for PPIs and H2RAs. We also assessed rate ratios of PPIs and H2RAs prescription rates to examine changes in prescribing over time.ResultsOur cohort included 177 477 children with a first ever diagnosis of gastroesophageal reflux during the study period. The median age was 13 years (IQR: 1, 17) among children prescribed PPIs and 0.2 years (IQR: 0.1, 0.6) among those prescribed H2RAs. The total prescription rate of all GERD drugs was 1468 prescriptions per 1000 person‐years (PYs) (95% CI 1463–1472). Overall, PPIs had a higher prescription rate (815 per 1000 PYs, 95% CI 812–818) than H2RAs (653 per 1000 PYs 95% CI 650–655). Sex‐ and age‐adjusted rate ratios of 2019 versus 1998 demonstrated a 10% increase and a 76% decrease in the prescription rates of PPIs and H2RAs, respectively.ConclusionsPrescription rates for PPIs increased, especially during the first half of the study period, while prescription rates for H2RA decreased over time.